Glucagon-like peptide 1 receptor agonist (GLP-1RA) compounds have become game changers in the treatment of obesity, but they have limitations due to long-term efficacy, lean mass preservation and tolerability in certain populations. Mitorx Therapeutics Ltd. has presented data for MTRX-31 (Myo-004), a mitochondrial-targeted compound that provides an alternative mode of action for treating obesity.